Biotechnology company INOVIO (INO) announced Monday that the U.S. Food and Drug Administration (FDA) has notified the company that it has additional questions about the company's planned Phase 2/3 trial of its COVID-19 vaccine candidate INO-4800, including its CELLECTRA 2000 delivery device to be used in the trial.
from RTT - Biotech https://ift.tt/36cNVkJ
via IFTTT
No comments:
Post a Comment